首页> 外文期刊>Asian Journal of Medical Sciences >The intravenous use of commercial disinfectants in the treatment of Novel Coronavirus (COVID-19): Unconventional, but is there evidence against it?
【24h】

The intravenous use of commercial disinfectants in the treatment of Novel Coronavirus (COVID-19): Unconventional, but is there evidence against it?

机译:静脉注射商业消毒剂在新型冠状病毒(Covid-19)的治疗中:非常规,但有证据吗?

获取原文
       

摘要

Background: On 24th April 2020, United States President Donald J. Trump suggested the use of commercial surface disinfectants to treat patients infected with COVID-19. In his?speech, President Trump also proposed medical research be conducted. However, there are controversies regarding the toxicity of the disinfectant’s main ingredients sodium hypochlorite. Aims and Objective: The purpose of this international collaborative study is to assess on feasibility and safety of disinfectants in human use. Materials and Methods: Several safety labels of common commercialised brands of surface disinfectant from United Kingdom and New Zealand. Furthermore, literature search was conducted through Pubmed on keywords keywords “sodium hypochlorite” AND “poisoning” AND “intravenous drug user”. Result: All safety labels advised hazardous warning regarding irritation and caustic burns if ingested. They all suggest water to wash out the effect if exposed to any mucus membrane such as eyes and broken skin. No safety information was given by any of the brands against?subcutaneous or intravenous injection. No death in human was reported resulting from?oral ingestion. There were 2 case reports: one of blindness and one of fibrosing alveolitis?resulting from ingestion during a domestic dispute. Intravenous injection has only been seen in attempted murder cases or by intravenous drug users. All the reported cases have resulted in 2 deaths, organ failures and venous thrombosis including pulmonary?embolism. Conclusion: There is no safety warning from the manufacturers of the studied surface disinfectants regarding intravenous use. Intravenous injections in the literature suggests significant toxic outcome including death. Randomised controlled trials on animals may be required to assess the risk of intravenous injection of surface disinfectants against the risk of death from COVID-19 infection.
机译:背景:4月24日2020年4月24日,美国总统唐纳德J.特朗普建议使用商业表面消毒剂治疗感染Covid-19的患者。在他的讲话中,特朗普总统还提出了拟议的医学研究。然而,存在关于消毒剂主要成分次氯酸钠的毒性的争论。目的和目标:本国际协同研究的目的是评估人类使用中消毒剂的可行性和安全性。材料与方法:来自英国和新西兰的普通商业化品牌的几种安全标签。此外,文献搜索是通过Pubmed在关键词关键词“次氯酸钠”和“中毒”和“静脉注射药物”中进行的。结果:如果摄入,所有安全标签都建议有关刺激和腐蚀性烧伤的危险警告。如果暴露于任何粘膜膜如眼睛和破碎的皮肤,它们都建议水冲洗效果。任何品牌都没有安全信息,反对皮下或静脉注射。据报道,人类没有死亡?口服摄取。有2例报告:盲目和敌肺炎的一个例外之一?由于在国内争议期间摄入而导致。静脉注射仅在企图谋杀病例或静脉注射药物中被出现。所有报告的病例都导致2例死亡,器官失败和静脉血栓形成,包括肺栓塞。结论:研究的表面消毒剂制造商没有安全警告关于静脉注射使用。文献中的静脉注射表明包括死亡的显着毒性结果。可能需要对动物的随机对照试验来评估静脉注射表面消毒剂免受来自Covid-19感染死亡风险的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号